Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $42.33

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received an average recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $42.33.

KROS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Keros Therapeutics in a research note on Tuesday. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Finally, Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of KROS. Victory Capital Management Inc. acquired a new position in shares of Keros Therapeutics during the third quarter valued at about $216,000. Intech Investment Management LLC bought a new position in Keros Therapeutics in the 3rd quarter valued at about $603,000. Charles Schwab Investment Management Inc. boosted its stake in Keros Therapeutics by 14.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after purchasing an additional 32,492 shares during the last quarter. FMR LLC increased its holdings in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Keros Therapeutics by 59.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock worth $312,000 after purchasing an additional 1,994 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Trading Down 6.3 %

Shares of KROS opened at $9.55 on Friday. The stock’s 50-day moving average price is $11.10 and its two-hundred day moving average price is $33.64. Keros Therapeutics has a 12 month low of $9.41 and a 12 month high of $72.37. The company has a market capitalization of $387.37 million, a PE ratio of -1.83 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Equities research analysts predict that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.